Side Effects of deutetrabenazine: A Synthesis of Findings from 17 Studies

  1. Home
  2. Side Effects of deutetrabenazine
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of deutetrabenazine: A Synthesis of Findings from 17 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of deutetrabenazine: A Synthesis of Findings from 17 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Deutetrabenazine is a VMAT-2 inhibitor used to treat movement disorders by blocking the release of dopamine. 10 suggests that deutetrabenazine may be an effective treatment for stuttering, as it reduces dopamine activity without the risk of metabolic adverse events. 6 suggests that deutetrabenazine may have fewer side effects than tetrabenazine, due to its deuterated form which slows metabolism and prolongs half-life, leading to greater safety and effectiveness. 9 suggests that deutetrabenazine has fewer peak-dose side effects than tetrabenazine in treating Huntington's disease.

Reason for Side Effects

Deutetrabenazine works by inhibiting the release of dopamine, which plays a crucial role in movement, mood, and cognitive functions. This inhibition can lead to side effects that impact these functions. 13 5

Common Side Effects

Parkinsonism

Deutetrabenazine can cause Parkinsonism. 2 Parkinsonism is a neurological disorder characterized by tremors, rigidity, slowness of movement, and postural instability.

Nausea and Vomiting

Deutetrabenazine can cause nausea and vomiting. 9 These side effects usually appear early in treatment and tend to improve as treatment continues.

Fatigue

Deutetrabenazine can cause fatigue. 9 Fatigue usually appears early in treatment and tends to improve as treatment continues.

Dizziness

Deutetrabenazine can cause dizziness. 9 Dizziness usually appears early in treatment and tends to improve as treatment continues.

Sleepiness

Deutetrabenazine can cause sleepiness. 9 Sleepiness usually appears early in treatment and tends to improve as treatment continues.

Constipation

Deutetrabenazine can cause constipation. 9 Constipation usually appears early in treatment and tends to improve as treatment continues.

Weight Gain

Deutetrabenazine can cause weight gain. 9 Weight gain usually appears early in treatment and tends to improve as treatment continues.

Depression

Deutetrabenazine can cause depression. 9 Depression usually appears early in treatment and tends to improve as treatment continues.

Suicidal Thoughts

Deutetrabenazine can cause suicidal thoughts. 9 Suicidal thoughts usually appear early in treatment and tend to improve as treatment continues.

Cognitive Impairment

Deutetrabenazine can cause cognitive impairment. 9 Cognitive impairment usually appears early in treatment and tends to improve as treatment continues.

Hallucinations

Deutetrabenazine can cause hallucinations. 9 Hallucinations usually appear early in treatment and tend to improve as treatment continues.

Delusions

Deutetrabenazine can cause delusions. 9 Delusions usually appear early in treatment and tend to improve as treatment continues.

Countermeasures for Side Effects

Parkinsonism

Parkinsonism can be treated with medication. 2 It may be necessary to reduce or stop the dose of deutetrabenazine.

Nausea and Vomiting

Nausea and vomiting can be treated with medication. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Fatigue

Fatigue can be treated with medication. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Dizziness

Dizziness can be treated with medication. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Sleepiness

Sleepiness can be treated with medication. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Constipation

Constipation can be treated with medication or lifestyle changes. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Weight Gain

Weight gain can be prevented or improved with diet and exercise. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Depression

Depression can be treated with medication or psychotherapy. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Suicidal Thoughts

Suicidal thoughts can be treated with psychotherapy and medication. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Cognitive Impairment

Cognitive impairment can be treated with medication or rehabilitation. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Hallucinations

Hallucinations can be treated with medication. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Delusions

Delusions can be treated with medication. 9 It may be necessary to reduce or stop the dose of deutetrabenazine.

Comparison Between Studies

Commonalities Between Studies

Many studies suggest that deutetrabenazine has fewer side effects than tetrabenazine. 6 9 These studies show that deutetrabenazine has a lower metabolic rate and a longer half-life than tetrabenazine. This suggests that deutetrabenazine may have fewer side effects than tetrabenazine.

Differences Between Studies

The effects and side effects of deutetrabenazine vary between studies. 6 9 The effects and side effects of deutetrabenazine may vary depending on the patient's condition and the dose administered.

Points to Note About Applying to Real Life

Deutetrabenazine works by inhibiting dopamine release, which plays a crucial role in movement, mood, and cognitive functions. Inhibiting dopamine release can affect these functions. 13 5 Therefore, you need to be aware of these side effects when taking deutetrabenazine.

Limitations of Current Research

Research on deutetrabenazine is still limited. 6 9 Further research is needed on the long-term effects and side effects of deutetrabenazine.

Future Research Directions

Further research is needed on the long-term effects and side effects of deutetrabenazine. 6 9 Comparative studies with other drugs are also needed to confirm the effectiveness and safety of deutetrabenazine.

Conclusion

Deutetrabenazine is a promising treatment for movement disorders. However, deutetrabenazine has the risk of side effects such as Parkinsonism. 2 You need to be aware of these side effects when taking deutetrabenazine. 13 5 Further research is needed on the long-term effects and side effects of deutetrabenazine. 6 9

Literature analysis of 17 papers
Positive Content
13
Neutral Content
2
Negative Content
2
Article Type
0
0
0
9
15
1.

Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer.

Author: BeleteTafere Mulaw

Improved efficacy
Improved safety
Increased half-life
Reduced dose

Deuterium incorporation is a promising approach to improve drug safety and efficacy by reducing metabolism and increasing half-life. This review discusses the deuterium kinetic isotope effect on drug metabolism and the development of deuterated anticancer drugs.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

2.

New generation VMAT2 inhibitors induced parkinsonism.

Author: VasireddyRani Priyanka, SokolaBrent, GuduruZain

Drug-induced parkinsonism
Unmask Parkinson's

Valbenazine and deutetrabenazine, VMAT-2 inhibitors, can cause drug-induced parkinsonism, unmasking underlying Parkinson's disease. Potential side effects of these drugs include muscle stiffness, tremors, and difficulty moving.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

3.

Benign Presentation Following Massive Deutetrabenazine Overdose.

Author: ObadeyiOluseyi, PaxtonJames H, KouyoumjianSarkis

Improved chorea symptoms
Overdose

Deutetrabenazine is a new drug for the treatment of tardive dyskinesia (TD). This case report describes a patient who overdosed on deutetrabenazine and experienced limited side effects, suggesting a good safety profile for this drug.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

4.

Recent developments in drug-induced movement disorders: a mixed picture.

Author: FactorStewart A, BurkhardPierre R, CaroffStanley, FriedmanJoseph H, MarrasConnie, TinazziMichele, ComellaCynthia L

Parkinsonism diagnosis
Tardive syndromes treatment
Movement disorders
Parkinsonism
Tardive syndromes

This study discusses the increasing prevalence of drug-induced movement disorders, particularly associated with antipsychotic medications. While these disorders can be disabling, recent advancements in diagnosis and treatment, including the approval of valbenazine and deutetrabenazine, offer hope for improved outcomes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals.

Author: RussakEdward M, BednarczykEdward M

Huntington's Disease Treatment
Tardive Dyskinesia Treatment

Deuterium-labeled drugs, such as deutetrabenazine, offer potential advantages over their non-deuterated counterparts by affecting pharmacokinetic and metabolic profiles. This is leading to the development of deuterated drugs for various diseases.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

7.

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Author: NiemannNicki, JankovicJoseph

VMAT2 inhibitor treatment
Tardive dyskinesia

This review discusses the treatment of tardive dyskinesia (TD), focusing on the vesicular monoamine transporter 2 (VMAT2) inhibitors, which are considered the treatment of choice for most patients with TD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Valbenazine for the treatment of tardive dyskinesia.

Author: MüllerThomas

Tardive dyskinesia treatment
Motor side effects
Psychopathological side effects

Valbenazine, a selective inhibitor of vesicular monoamine transporter 2, is a promising treatment option for tardive dyskinesia (TD). Compared to tetrabenazine, valbenazine may have fewer side effects and a more favorable once-daily dosing regimen.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Case Report: Deutetrabenazine as an Adjunctive Treatment for Stuttering.

Author: HaCatherine A, MaguireGerald A

Reduced dopamine activity
Stuttering treatment
Metabolic side effects
Movement disorders

Deutetrabenazine, a VMAT-2 inhibitor, is a potential candidate for the treatment of stuttering due to its ability to decrease dopamine activity without the metabolic side effects of antipsychotics. Further research is needed to confirm its efficacy and safety.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Language : English

12.

Tardive Dyskinesia: Treatment Update.

Author: AryaDivya, KhanTarannum, MargoliusAdam J, FernandezHubert H

TD management

Tardive dyskinesia (TD) is a debilitating side effect of antipsychotic medications. This review examines recent advancements in the understanding and management of TD, including new treatment options and approaches to prevention.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Real-World Experience With VMAT2 Inhibitors.

Author: NiemannNicki, JankovicJoseph

Hyperkinetic movement disorders treatment
Insurance and regulatory issues
Physician inexperience
Side effects

VMAT2 inhibitors like tetrabenazine, deutetrabenazine, and valbenazine are used to treat hyperkinetic movement disorders. However, access and adherence can be limited by insurance, physician experience, efficacy, and side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Pragmatic Clinical TrialA trial conducted in a real-world clinical setting. It evaluates the effectiveness of interventions in everyday healthcare environments.

Language : English

15.

An Update on the Treatment of Chorea.

Author: FeinsteinErin, WalkerRuth

Chorea management

This review focuses on the management of chorea due to untreatable causes. Chorea can be caused by various factors, including genetics, autoimmune disorders, medications, and structural lesions. Treatment generally focuses on reversing the underlying cause, with many cases resolving when the primary disorder is treated.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Clinical risk factors for the development of tardive dyskinesia.

Author: SolmiMarco, PigatoGiorgio, KaneJohn M, CorrellChristoph U

Tardive dyskinesia

Tardive dyskinesia (TD) is a serious side effect of antipsychotic treatment. While new treatments like deutetrabenazine and valbenazine are available, prevention of TD remains crucial due to limited effectiveness and recurrence after treatment discontinuation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.